

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wesley Peter Blackaby, et al.

Int'l Appln.
No. : PCT/GB03/03376

Int'l Date
Filed : 04 August 2003 (04/08/2003)

Serial No. : (To be assigned) Case No.: T1569YP

Filed : February 13, 2005

For : PHENYLPYRIDAZINE DERIVATIVES AS LIGANDS
FOR GABA RECEPTORS

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 2/8/2005
EXPRESS MAIL NO. EL 989587757 US
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Sabrina B. Crowley
DATE 2/8/05

10/524173

Serial No.: To be assigned
Case No.: T1569YP

Page 2
DT05 Rec'd PCT/PTO 08 FEB 2005

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



J. Eric Thies
Reg. No. 35,382
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-3904

Date: February 13, 2005

COMPLETELY KNOWN

~~10/524173~~

DTIC Rec'd POTA PTO 08 FEB 2005

February 23, 2015

08 FEB 2005

Wesley Peter Blackaby et al

T1569YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE INFORMATION		
			Application Number DT05 Rec'd PCT/PTO 10/524173		
			Filing Date 08 FEB 2005		
			First Named Inventor Wesley Peter Blackaby et al		
			Group Art Unit		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	T1569YP

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Wermuth, Camille Georges et al: "Synthesis and structure-activity relationships of a series of aminopyridazine derivatives of gamma - aminobutyric acid acting as selective GABA-A antagonists", JOURNAL OF MEDICINAL CHEMISTRY (1987) 30(2), 239-49.
		Auricchio, Sergio et al: "New cleavage of the azirine ring by single electron transfer: the synthesis of 2H-imidazoles, pyridazines and pyrrolines", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2001), (6), 1183-1187.
		Rival, Yveline et al: "5-HT3 Antagonists Derived from Aminopyridazine-type Muscarinic M1 Agonist", JOURNAL OF MEDICINAL CHEMISTRY (1998), 41(3), 311-317.
		South, Michael S. et al: "Synthesis and Reactions of Haloazodienes, A New and General Synthesis of Substituted Pyridazines", JOURNAL OF ORGANIC CHEMISTRY (1996), 61(25), 8921-8934.
		Bly, Ruta K. et al: "Heterocyclic studies, XIII. The aldol condensation of 2,3-dihydro-5-methyl-6-phenyl-4H-1, 2diazepin-4-one and rearrangement to a pyridazine", JOURNAL OF ORGANIC CHEMISTRY (1964), 29(8), 2128-35.
		Chem. Abstract, XP002257945, 53:67737 Chemical Abstracts Service, Columbus, Ohio, US; Atkinson, C. M. et al: "Triazaphenanthrenes. III. Synthesis of some 9-aryl-2,3,10- triazaphenanthrenes", JOURNAL OF THE CHEMICAL SOCIETY, (1959) 1-5
		Chem. Abstract, XP002257946, 126:18740 Chemical Abstracts Service, Columbus, Ohio, US; Samsonov, V. A. et al: "Preparation and reactions of pyrroline N-oxides obtained by reaction of isonitroso ketones with enamines", KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII (1996), (8), 1055-1061.
		Harris, R.L.N. et al.: "The effect of C-2-carboxyphenyl Derivatives of Certain Heterocyclic Compounds on Root Geotropism in Cress Seedlings" PESTICIDE SCIENCE, vol. 11, 1980, pages 439-444.
		Oliver, J.E. et al.: "Alkylating and Rearrangement of Lithiated 3-Methyl-1,2-benzisoxazoles", JOURNAL OF ORGANIC CHEMISTRY, vol. 54, 1989, pages 4970-4973.
		Breukelman, S.P.: "Preparation and some Reaction of 4- and 5-Aryl-4,5-dihydropyrazin-3(2H-ones)" J. CHEM. SOC. PERKIN TRANS., 1985, pages 1627-1635.
		Jojma, T. et al.: "Pyridazine I. Novel Intramolecular Cycloaddition of 3-Chloro-6-(2-allylphenoxy)pyridazines" CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 20, no. 10, - 1972 pages 2191-2203.

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003